zur Suche springenzur Navigation springenzum Inhalt springen

Sortieren nach: Erscheinungsjahr Typ der Publikation

Zeige Ergebnisse 1 bis 2 von 2.

Publikation

Buchholz, M.; Brandt, W.; Hoffmann, T.; Schilling, S.; Demuth, H.-U.; Heiser, U.; Optimization of inhibitors for human glutaminyl cyclase by structure based design and bio-isosteric replacement Drug. Future 34, 186, (2009)

0
Publikation

Buchholz, M.; Hamann, A.; Aust, S.; Brandt, W.; Böhme, L.; Hoffmann, T.; Schilling, S.; Demuth, H.-U.; Heiser, U.; Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement J. Med. Chem. 52, 7069-7080, (2009) DOI: 10.1021/jm900969p

The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer’s disease. The hallmark of this principle is the prevention of the formation of Aβ3,11(pE)-40,42, as these Aβ-species were shown to be of elevated neurotoxicity and likely to act as a seeding core leading to an accelerated formation of Aβ-oligomers and fibrils. Starting from 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea, bioisosteric replacements led to the development of new classes of inhibitors. The optimization of the metal-binding group was achieved by homology modeling and afforded a first insight into the probable binding mode of the inhibitors in the hQC active site. The efficacy assessment of the hQC inhibitors was performed in cell culture, directly monitoring the inhibition of Aβ3,11(pE)-40,42 formation.
IPB Mainnav Search